"Graft vs Host Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Descriptor ID |
D006086
|
MeSH Number(s) |
C20.452
|
Concept/Terms |
Graft vs Host Disease- Graft vs Host Disease
- Graft-Versus-Host Disease
- Disease, Graft-Versus-Host
- Diseases, Graft-Versus-Host
- Graft Versus Host Disease
- Graft-Versus-Host Diseases
- Runt Disease
- Disease, Runt
- Graft-vs-Host Disease
- Disease, Graft-vs-Host
- Diseases, Graft-vs-Host
- Graft-vs-Host Diseases
- Homologous Wasting Disease
- Disease, Homologous Wasting
|
Below are MeSH descriptors whose meaning is more general than "Graft vs Host Disease".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Host Disease".
This graph shows the total number of publications written about "Graft vs Host Disease" by people in this website by year, and whether "Graft vs Host Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2007 | 2 | 0 | 2 |
2013 | 1 | 0 | 1 |
2017 | 0 | 2 | 2 |
2018 | 0 | 1 | 1 |
2019 | 1 | 1 | 2 |
2020 | 3 | 0 | 3 |
2021 | 3 | 0 | 3 |
2022 | 3 | 0 | 3 |
2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Graft vs Host Disease" by people in Profiles.
-
Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 Jan; 59(1):76-84.
-
Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Transplant Cell Ther. 2024 Jan; 30(1):114.e1-114.e16.
-
Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 10; 57(10):1632-1634.
-
Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2022 07; 57(7):1150-1163.
-
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
-
Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report. Transplant Proc. 2022 Jan-Feb; 54(1):176-179.
-
Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021 12 14; 5(23):5047-5056.
-
Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplant Cell Ther. 2022 06; 28(6):335.e1-335.e17.
-
Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Adv. 2020 05 26; 4(10):2317-2324.
-
Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.